<VariationArchive VariationID="463500" VariationName="NM_000077.5(CDKN2A):c.340_355del (p.Pro114fs)" VariationType="Deletion" Accession="VCV000463500" Version="12" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-07-29" DateCreated="2018-05-26" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="459948" VariationID="463500">
      <GeneList>
        <Gene Symbol="CDKN2A" FullName="cyclin dependent kinase inhibitor 2A" GeneID="1029" HGNC_ID="HGNC:1787" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>9p21.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="21967752" stop="21995324" display_start="21967752" display_stop="21995324" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="21967750" stop="21994489" display_start="21967750" display_stop="21994489" Strand="-" />
          </Location>
          <OMIM>600160</OMIM>
          <Haploinsufficiency last_evaluated="2022-03-18" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CDKN2A">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-03-18" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CDKN2A">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000077.5(CDKN2A):c.340_355del (p.Pro114fs)</Name>
      <CanonicalSPDI>NC_000009.12:21971003:CAGCCAGGTCCACGGGCAG:CAG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>9p21.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="21971004" stop="21971019" display_start="21971004" display_stop="21971019" variantLength="16" positionVCF="21971003" referenceAlleleVCF="TCAGCCAGGTCCACGGG" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="21971003" stop="21971018" display_start="21971003" display_stop="21971018" variantLength="16" positionVCF="21971002" referenceAlleleVCF="TCAGCCAGGTCCACGGG" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>P114fs</ProteinChange>
      <ProteinChange>P63fs</ProteinChange>
      <ProteinChange>A128fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000077.4" sequenceAccession="NM_000077" sequenceVersion="4" change="c.340_355delCCCGTGGACCTGGCTG">
            <Expression>NM_000077.4:c.340_355delCCCGTGGACCTGGCTG</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.11" sequenceAccession="NC_000009" sequenceVersion="11" change="g.21971006_21971021del" Assembly="GRCh37">
            <Expression>NC_000009.11:g.21971006_21971021del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.12" sequenceAccession="NC_000009" sequenceVersion="12" change="g.21971007_21971022del" Assembly="GRCh38">
            <Expression>NC_000009.12:g.21971007_21971022del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007485.1" sequenceAccession="NG_007485" sequenceVersion="1" change="g.28473_28488del">
            <Expression>NG_007485.1:g.28473_28488del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000077.5" sequenceAccession="NM_000077" sequenceVersion="5" change="c.340_355del" MANESelect="true">
            <Expression>NM_000077.5:c.340_355del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000068.1" sequenceAccession="NP_000068" sequenceVersion="1" change="p.Pro114fs">
            <Expression>NP_000068.1:p.Pro114fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001195132.2" sequenceAccession="NM_001195132" sequenceVersion="2" change="c.340_355del">
            <Expression>NM_001195132.2:c.340_355del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001182061.1" sequenceAccession="NP_001182061" sequenceVersion="1" change="p.Pro114fs">
            <Expression>NP_001182061.1:p.Pro114fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001363763.2" sequenceAccession="NM_001363763" sequenceVersion="2" change="c.187_202del">
            <Expression>NM_001363763.2:c.187_202del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001350692.1" sequenceAccession="NP_001350692" sequenceVersion="1" change="p.Pro63fs">
            <Expression>NP_001350692.1:p.Pro63fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_058195.4" sequenceAccession="NM_058195" sequenceVersion="4" change="c.383_398del" MANEPlusClinical="true">
            <Expression>NM_058195.4:c.383_398del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_478102.2" sequenceAccession="NP_478102" sequenceVersion="2" change="p.Ala128fs">
            <Expression>NP_478102.2:p.Ala128fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_058197.5" sequenceAccession="NM_058197" sequenceVersion="5" change="c.*263_*278del">
            <Expression>NM_058197.5:c.*263_*278del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_11" sequenceAccession="LRG_11">
            <Expression>LRG_11:g.28473_28488del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_11t1" sequenceAccession="LRG_11t1">
            <Expression>LRG_11t1:c.340_355del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_11p1" sequenceAccession="LRG_11p1" change="p.Pro114fs">
            <Expression>LRG_11p1:p.Pro114fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA658656026" DB="ClinGen" />
        <XRef Type="rs" ID="1554653956" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000077.5(CDKN2A):c.340_355del (p.Pro114fs) AND Familial melanoma" Accession="RCV000532665" Version="16">
        <ClassifiedConditionList TraitSetID="13761">
          <ClassifiedCondition DB="MedGen" ID="C1512419">Familial melanoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-07-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000077.5(CDKN2A):c.340_355del (p.Pro114fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV002456105" Version="10">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-01-31" SubmissionCount="2">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-07-14" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2018-05-26" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">25780468</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26681309</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29506128</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8880901</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9439668</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20539244</ID>
        </Citation>
        <DescriptionHistory Dated="2024-02-17">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="13761" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18483" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial melanoma</ElementValue>
                <XRef ID="MONDO:0018961" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary melanoma</ElementValue>
                <XRef ID="C8498" DB="NCI" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary cutaneous melanoma</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3460" />
                <XRef ID="3460" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2022">
                <URL>https://www.nice.org.uk/guidance/ng14</URL>
                <CitationText>UK NICE Guideline NG14, Melanoma: assessment and management, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Melanoma: Cutaneous, 2024</CitationText>
              </Citation>
              <XRef ID="618" DB="Orphanet" />
              <XRef ID="C1512419" DB="MedGen" />
              <XRef ID="MONDO:0018961" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8048284" SubmissionDate="2024-01-25" DateLastUpdated="2024-02-14" DateCreated="2024-02-14">
        <ClinVarSubmissionID localKey="Db4KrQBSZeoE7-orUyypkaOmRlxuNCESY4OrYKDmgpI|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004361300" DateUpdated="2024-02-14" DateCreated="2024-02-14" Type="SCV" Version="1" SubmitterName="Color Diagnostics, LLC DBA Color Health" OrgID="505849" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-01-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8880901</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29506128</ID>
          </Citation>
          <Comment>The CDKN2A locus encodes two different gene products, p16INK4a and p14ARF (https://www.ncbi.nlm.nih.gov/books/NBK7030/ ). This variant deletes 16 nucleotides in exon 2 of the CDKN2A (p16INK4A) gene, creating a frameshift and premature translation stop signal in exon 2. This variant is expected to result in the expression of a truncated protein with the sequence of the C-terminal region, including functionally important ankyrin repeat 4, disrupted (PMID: 8880901). Although functional studies have not been reported, this variant is expected to impair CDKN2A (p16INK4A) protein function. This variant has been reported in an individual affected with exocrine pancreatic cancer (PMID: 29506128). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Other truncation variants impacting ankyrin repeat 4 are known to be pathogenic, which include c.358del (p.Glu120Serfs*26, ClinVar variation ID: 406710) and c.457G&gt;T (p.Asp153Tyr; splice variant causing r.384_457del; p.Tyr129Hisfs*11) (ClinVar variation ID: 216035). Loss of CDKN2A function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Likely Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <TypePlatform>NGS</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CDKN2A" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000077.5:c.340_355del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14171678</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1229916" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="1825049|MedGen:C1512419" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000637415" DateUpdated="2024-02-20" DateCreated="2017-12-26" Type="SCV" Version="7" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">29506128</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9439668</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20539244</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20653773</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25780468</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26681309</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Pro114Argfs*27) in the CDKN2A (p16INK4a) gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 43 amino acid(s) of the CDKN2A (p16INK4a) protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with pancreatic cancer (PMID: 29506128). This variant is also known as c.383_398del (p.Ala128Glufs*39) in the CDKN2A (p14ARF) transcript. ClinVar contains an entry for this variant (Variation ID: 463500). This variant disrupts a region of the CDKN2A (p16INK4a) protein in which other variant(s) (p.Val126Asp) have been determined to be pathogenic (PMID: 9439668, 20539244, 20653773, 25780468, 26681309). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. While the evidence indicates that this variant confers risk of developing CDKN2A (p16INK4a)-associated conditions, its association with risk for developing CDKN2A (p14ARF)-associated conditions is still unclear. The CDKN2A gene encodes two different proteins, p16INK4a and p14ARF, which are translated from alternative transcripts with different open reading frames. Both transcripts have been analyzed. We report either the variant with the higher classification or default to the CDKN2A (p16INK4a) variant. This report therefore includes the details for the CDKN2A (p16INK4a) variant.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CDKN2A" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000009.11:g.21971003_21971018del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1512419" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5098872" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2022-11-29">
        <ClinVarSubmissionID localKey="a329329|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002612700" DateUpdated="2024-05-01" DateCreated="2022-11-29" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-07-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">29506128</ID>
          </Citation>
          <Comment>The c.340_355del16 variant, located in coding exon 2 of the CDKN2A gene, results from a deletion of 16 nucleotides at nucleotide positions 340 to 355, causing a translational frameshift with a predicted alternate stop codon (p.P114Rfs*27). This alteration occurs at the 3' terminus of theCDKN2A gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 43 amino acids of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function (Ambry internal data). Multiple downstream truncations in CDKN2A have been reported in families with cutaneous malignant melanoma and/or pancreatic cancers (De Unamuno B et al. Melanoma Res, 2018 06;28:246-249; Puig S et al. Hum Genet, 1997 Dec;101:359-64; Ruiz A et al. J Med Genet 1999 Jun;36:490-3; Potrony M et al J Am Acad Dermatol, 2014 Nov;71(5):888-95). This variant has been reported in a cohort of unselected patients with exocrine pancreatic neoplasms (Lowery MA et al. J Natl Cancer Inst, 2018 10;110:1067-1074). In addition to the clinical data presented in the literature, based on the majority of available evidence to date, this variant is likely to be pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CDKN2A" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000077.4:c.340_355del16</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5098872" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8048284" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1229916" TraitType="Disease" MappingType="XRef" MappingValue="C1512419" MappingRef="MedGen">
        <MedGen CUI="C1512419" Name="Familial melanoma" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

